An observational study in Menopause, sponsored by Université de Sherbrooke. Recruiting at 2 sites in Canada. Open to female participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Université de Sherbrooke · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Ketosis by Université de Sherbrooke — 4 open to participants now, 5 under way, none of them phase 3. Ketosis · Université de Sherbrooke.
Among the 18 studies in Ketosis by Université de Sherbrooke, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 17th registered.
218 studies on the registry are indexed under Ketosis; 49 are open to participants now.
Browse Ketosis studies →4 of the 18 studies in Ketosis by Université de Sherbrooke are open now, in 1 country. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18–35
Université de Sherbrooke · Sites in Canada
Ages 18–35
Université de Sherbrooke · Sites in Canada
Ages 60+ · Healthy volunteers
By country, each count listing its studies:
Of the 31 Ketosis studies recruiting now, 7 (23%) set no upper age limit and 21 (68%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 35 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 45 is below the median of 58 across 23 observational studies indexed under Ketosis.
Median enrollment 15 across the 15 interventional studies, 18 across the 3 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
3 of the studies in Ketosis by Université de Sherbrooke that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05968391Université de SherbrookeAcetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) | 2026-12-15 |
| NCT07021664Université de SherbrookeHealth, Imaging, and Cognition Across the Menopausal Transition | 2027-04-01 |
| NCT07122531Université de SherbrookeRecovery With Exogenous Ketones and Antipsychotics | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Ketosis by Université de Sherbrooke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational cross-sectional study aims to better understand how the menopausal transition affects brain energy metabolism and cognition. Menopause, a natural stage in a woman's life, is typically divided into three phases: premenopause, perimenopause, and postmenopause. This transition involves hormonal fluctuations and a decline in estrogen levels, which can impact physical, emotional, and cognitive well-being. Common symptoms include hot flashes, sleep disturbances, mood changes, and difficulties with memory and concentration.
Emerging evidence suggests that the decline in estrogen may impair how the brain uses glucose, its primary energy source. This reduction in glucose metabolism is thought to contribute to cognitive difficulties reported during midlife. In contrast, the brain's capacity to use ketones-alternative energy substrates produced during fasting or low-carbohydrate intake-appears preserved during aging and hormonal changes. Increasing circulating ketones may offer a promising strategy to support brain energy and cognitive function.
To explore these relationships, the study will employ advanced brain imaging (PET scans) to assess glucose and ketone uptake in the brain. Additional measures will include hormone levels, cognitive testing, continuous glucose monitoring, and MRI. PET tracers will also be used to evaluate estrogen receptor distribution, providing insight into how the brain responds to hormonal changes.
A total of 45 women aged 35-60 will be enrolled and categorized into three groups (15 per group): premenopause, perimenopause, and postmenopause. Each participant will attend four study visits that include questionnaires, blood tests, cognitive assessments, metabolic measurements, and imaging procedures.
The results may help identify early neurobiological and metabolic markers associated with the menopausal transition. These findings could inform new approaches to preserve brain health and prevent cognitive decline in aging women. Improving understanding of how the female brain adapts to hormonal shifts may ultimately support more targeted strategies for promoting healthy aging.
Healthy individuals from the general population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Perimenopause: Women aged 40 to 60; Menstrual cycles varying by more than 7 days per cycle for at least 10 cycles, or no period for 3 to 11 months
: Women aged 45 to 65; No menstrual period for ≥ 12 months
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women between 35 and 55 years old who still have regular menstrual cycles, with no noticeable changes in the past 10 months.
Women between 40 and 60 years old who have experienced changes in their menstrual cycles, such as irregular timing (varying by more than 7 days) for at least 10 cycles, or no period for 3 to 11 months.
Women between 45 and 65 years old who have not had a menstrual period for 12 months or more.
cerebral metabolic rates (μmol/100 g/min) measured by PET (11C-AcAc +18F-FDG)
Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST).Total Cerebral metabolic rates (μmol/100 g/min) (CMR tot= CMR acac + CMRglu)
Time frame: 1 day at baseline
Tracer influx rates (k) measured by PET (11C-AcAc +18F-FDG)
Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST). tracer influx rates (K values).
Time frame: 1 day at baseline
Time-activity curves of the estrogen receptor in the brain (by 18F-4FMFES PET)
Time-activity curves of the estrogen recept will be measured using 18F-4FMFES PET express as SUV (Standardized Uptake Value)
Time frame: 1 day at baseline
distribution volume ratio of the estrogen receptor in the brain (by 18F-4FMFES PET)
distribution volume ratio of the estrogen receptor will be measured by kinetic modelisation using 18F-4FMFES PET.
Time frame: 1 day at baseline
Glucose variability (SD of glucose measured by continuous glucose monitoring)
Continuous glucose monitoring (CGM) will track glucose levels over several days. Glycemic variability will be assessed by the standard deviation of glucose values over the 5 days monitoring period. (mmol/L)
Time frame: Over 5 days following sensor placement et stabilisation
Glucose average (mean of glucose measured by continuous glucose monitoring)
Continuous glucose monitoring (CGM) will track glucose levels over several days. Average glucose concentration over the monitoring period.(mmol/L)
Time frame: Over 5 days following sensor placement et stabilisation
Time in range
Total minutes with glucose values within the standard glycemic range (3.9-10.0 mmol/L) over the 5 days monitoring period. (min)
Time frame: Over 5 days following sensor placement et stabilisation
Brain volume
Will be measured by MRI - T1-weighted images and express in cm³
Time frame: 1 day at baseline
Rey Auditory Verbal Learning Test (RAVLT)
Assesses verbal memory. Total score (range: 0-75); higher scores indicate better performance
Time frame: 1 day at baseline
Stroop Color and Word test (Stroop Test) (secondes)
Measures processing speed and executive function; outcome is time to completion. Unit of Measure: Seconds; lower scores indicate better performance
Time frame: 1 day at baseline
Trail making test (secondes)
Assesses cognitive flexibility, visual attention, and processing speed. Unit of Measure: Seconds; lower scores indicate better performance
Time frame: 1 day at baseline
Montreal Cognitive Assessment (MoCA) score
Global cognitive screening tool. Unit of Measure: Score (range: 0-30); higher scores indicate better cognition.
Time frame: 1 day at baseline
Boston naming tests (total answer)
Measures language and word retrieval ability.Total correct responses (range: 0-60); higher scores are better
Time frame: 1 day at baseline
Symbol coding (score)
Assesses processing speed.Score (higher = better)
Time frame: 1 day at baseline
Logical Memory Subtest of the Wechsler Memory Scale-IV
Assesses elayed story recall. Score (0-25); higher scores indicate better memory
Time frame: 1 day at baseline
Fasting plasma glucose (mM)
Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups
Time frame: 1 day at baseline
Fasting plasma insulin (mM)
Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups
Time frame: 1 day at baseline
Fasting plasma HbA1c (%)
Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups
Time frame: 1 day at baseline
Fasting plasma total ketone (uM)
Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups. Total ketone = acetoacetate + beta-hydroxybutyrate
Time frame: 1 day at baseline
Estrogene levels (pmol/L)
Blood samples will be used to assess sex hormone and will be compared across 3 group
Time frame: 1 day at baseline
follicule stimulating hormone levels (mIU/mL)
Blood samples will be used to assess sex hormone and will be compared across 3 group
Time frame: 1 day at baseline
Progesterone (nmol/L)
Blood samples will be used to assess sex hormone and will be compared across 3 group
Time frame: 1 day at baseline
hormone lutéinisante (mUI/mL)
Blood samples will be used to assess sex hormone and will be compared across 3 group
Time frame: 1 day at baseline
Menopause-Specific Quality of Life Questionnaire
Self-reported questionnaires. Self-reported symptom burden. Unit of Measure: Score (range: 0-44); higher = more severe symptoms
Time frame: 1 day at baseline
Menopause Rating Scale
Self-reported symptom burden. Unit of Measure: Score (range: 0-44); higher = more severe symptoms
Time frame: 1 day at baseline
Pittsburgh Sleep Quality Index
Self-reported questionnaire. Assesses sleep quality over the past month. Unit of Measure: Score (range: 0-21); higher = poorer sleep
Time frame: 1 day at baseline
Patient Health Questionnaire (PHQ-9)
Depressive symptoms. Score (range: 0-27); higher = more severe depression
Time frame: 1 day at baseline
Subjective memory complain
Self-reported memory or concentration issues. Unit of Measure: Score (range 62-372) ; higher scores indicate more complaints
Time frame: 1 day at baseline
International Physical Activity Questionnaire
Physical activity over the past week. (MET-minutes/week)
Time frame: 1 day at baseline
Plan to share: Undecided — There is no current plan to share individual participant data (IPD) with external researchers. While data reuse within the study team is permitted, external data sharing is subject to sponsor agreement and may be considered on a case-by-case basis in the future.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2026 → Apr 2027 and completion Jul 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.